Patients treated with LONSURF (trifluridine and tipiracil) had a median overall survival of 5.7 months. This represents the typical duration from the start of treatment until a patient's passing in clinical trials.
Understanding Overall Survival in Cancer Treatment
Overall survival (OS) is a primary endpoint in clinical trials for cancer treatments. It measures the time from the beginning of treatment until the death of the patient from any cause. This metric is a crucial indicator of a therapy's effectiveness in extending life. For LONSURF, studies have demonstrated an improvement in this vital measure for patients with certain advanced cancers.
LONSURF vs. Placebo: Median Overall Survival Comparison
Clinical trials have shown that patients receiving LONSURF experienced an extended median overall survival compared to those who received only a placebo. This comparison underscores the drug's role in prolonging life for eligible patients.
| Treatment Group | Median Overall Survival |
|---|---|
| LONSURF | 5.7 months |
| Placebo | 3.6 months |
This data indicates that, on average, patients treated with LONSURF lived approximately 2.1 months longer than those who received only a placebo. It is important to note that these are median figures, meaning half of the patients lived longer than this duration, and half lived less. Individual patient outcomes can vary significantly based on numerous factors, including the specific type and stage of cancer, overall health, and previous treatments.
